Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GUN
Gunpoint Exploration
C$0.68
-2.9%
C$0.65
C$0.45
C$0.80
C$34.61M0.825,724 shs7,500 shs
Mechel PAO stock logo
MTL
Mechel PAO
$2.25
$2.28
$1.58
$5.19
N/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.08
-11.1%
$0.11
$0.07
$1.28
$2.90M2.033.27 million shs1.82 million shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GUN
Gunpoint Exploration
0.00%-2.86%-2.86%+36.00%+21.43%
Mechel PAO stock logo
MTL
Mechel PAO
0.00%0.00%0.00%0.00%0.00%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+0.34%-0.78%+3.00%-41.79%+8,929,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GUN
Gunpoint Exploration
N/AN/AN/AN/AN/AN/AN/AN/A
Mechel PAO stock logo
MTL
Mechel PAO
N/AN/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GUN
Gunpoint Exploration
N/AN/AN/AN/A
Mechel PAO stock logo
MTL
Mechel PAO
N/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GUN
Gunpoint Exploration
N/AN/AC$0.04 per share15.63C$0.14 per shareN/A
Mechel PAO stock logo
MTL
Mechel PAO
$5.46BN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.20N/AN/A$0.12 per share0.67

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GUN
Gunpoint Exploration
-C$1.02M-C$0.02N/AN/AN/A-13.44%-4.32%5/16/2024 (Estimated)
Mechel PAO stock logo
MTL
Mechel PAO
$1.10BN/A0.00N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.15N/A-65.46%-150.14%-53.48%5/28/2024 (Estimated)

Latest KDNC, GUN, NBY, and MTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GUN
Gunpoint Exploration
N/AN/AN/AN/AN/A
Mechel PAO stock logo
MTL
Mechel PAO
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GUN
Gunpoint Exploration
14.19
35.86
2.14
Mechel PAO stock logo
MTL
Mechel PAO
N/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
GUN
Gunpoint Exploration
N/A
Mechel PAO stock logo
MTL
Mechel PAO
N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%

Insider Ownership

CompanyInsider Ownership
GUN
Gunpoint Exploration
81.74%
Mechel PAO stock logo
MTL
Mechel PAO
36.34%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
0.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
GUN
Gunpoint Exploration
N/A50.89 millionN/ANot Optionable
Mechel PAO stock logo
MTL
Mechel PAO
51,414N/AN/AOptionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million36.03 millionNot Optionable

KDNC, GUN, NBY, and MTL Headlines

SourceHeadline
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial ResultsNovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
businesswire.com - May 9 at 4:05 PM
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.comNovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - May 9 at 3:42 AM
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through AmazonNovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
businesswire.com - May 7 at 8:00 AM
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
businesswire.com - May 3 at 6:50 AM
NovaBay Pharmaceuticals (NYSE:NBY) Earns Sell Rating from Analysts at StockNews.comNovaBay Pharmaceuticals (NYSE:NBY) Earns Sell Rating from Analysts at StockNews.com
americanbankingnews.com - May 1 at 2:14 AM
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova SalesNovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
businesswire.com - April 22 at 6:57 AM
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder EquityNovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
businesswire.com - April 19 at 6:00 PM
NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call TranscriptNovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 28 at 9:16 PM
NovaBay Pharmaceuticals: Q4 Earnings InsightsNovaBay Pharmaceuticals: Q4 Earnings Insights
benzinga.com - March 26 at 10:00 PM
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial ResultsNovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 26 at 10:00 PM
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
businesswire.com - March 25 at 6:38 PM
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
businesswire.com - March 14 at 8:00 AM
NioBay Metals closes option agreement to acquire Foothills propertyNioBay Metals closes option agreement to acquire Foothills property
markets.businessinsider.com - February 21 at 8:30 AM
A Guide To The Risks Of Investing In Novabay Pharmaceuticals Inc (NBY)A Guide To The Risks Of Investing In Novabay Pharmaceuticals Inc (NBY)
knoxdaily.com - January 31 at 8:40 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Gunpoint Exploration

CVE:GUN
Gunpoint Exploration Ltd. engages in the acquisition and exploration of precious metal properties in the United States, Mexico, and Guatemala. The company explores for gold, silver, copper, zinc, lead, and other deposits. Its flagship property is the 100% interest in the Talapoosa gold-silver project comprising 535 unpatented lode mining claims covering an area of approximately 14,870 acres located in Lyon County, Nevada. The company was incorporated in 1989 and is headquartered in Vancouver, Canada. Gunpoint Exploration Ltd. is a subsidiary of Chesapeake Gold Corp.
Mechel PAO logo

Mechel PAO

NYSE:MTL
Mechel PAO, together with its subsidiaries, engages in mining, steel, and power businesses in Russia, Asia, Europe, the Commonwealth of Independent States, and internationally. The Mining segment produces and sells coking and steam coals, middlings, coke and chemical products, and iron ore concentrate. The Steel segment produces and sells semi-finished steel products; carbon and specialty long products; carbon and stainless flat products; and value-added downstream metal products, including forgings, stampings, hardware, rails, and ferrosilicon. The Power segment generates and supplies electricity and heat power to the third parties. It also provides transportation and freight services. The company was formerly known as Mechel OAO and changed its name to Mechel PAO in March 2016. Mechel PAO was incorporated in 2003 and is based in Moscow, Russia.
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.